Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 296 Products   1145 Diseases   296 Products   3757 Trials   200588 News 


12345678910111213...22902291»
  • ||||||||||  Natrecor (nesiritide) / J&J, Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Januvia (sitagliptin) / Merck (MSD)
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1 (clinicaltrials.gov) -  Mar 11, 2025   
    P4,  N=4, Terminated, 
    Not yet recruiting --> Recruiting N=32 --> 4 | Trial completion date: Dec 2025 --> Dec 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2025 --> Dec 2024; An alternative study was developed to replace this study.
  • ||||||||||  Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma, Bionovis
    Journal:  Stabilization of Sb4 Tetrahedra in Paramagnetic Transition Metal Carbonyl Complexes. (Pubmed Central) -  Mar 11, 2025   
    Complex 1 exhibited versatile reactivities toward groups 7-9 metal carbonyls, dioxygen, or [Cu(MeCN)4][BF4] to form selective orbital-controlled Sb4-based products, including transmetalated paramagnetic complexes [Et4N]4[Sb4Cr5Mn(CO)28]Br ([Et4N]4[1-Mn]Br), [Et4N]4[Sb4Cr2Fe6(CO)30] ([Et4N]4[1-Fe]), and [Et4N]2[Sb4Cr4Co4(CO)31] ([Et4N]2[1-Co]), the dioxygen-activated paramagnetic cluster [Et4N]4[O2Sb4Cr6(CO)28] ([Et4N]4[1-O2]), or the spin-quenched complex [Et4N]2[Sb4Cr6(CO)28] ([Et4N]2[2]), respectively. The structural nature, bonding properties, paramagnetism, and semiconductivity of these unprecedented transition metal carbonyl-protected Sb4-based clusters were further realized with DFT calculations.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), rofecoxib (TRM-201) / Tremeau Pharma, celecoxib oral / Generic mfg.
    Journal, Adverse events:  Drug-Related Hypertension: A Disproportionality Analysis Leveraging the FDA Adverse Event Reporting System. (Pubmed Central) -  Mar 11, 2025   
    Some drugs, such as rofecoxib, lenvatinib, and celecoxib, were found to appear on both the frequency and signal strength lists. These results contribute to a more comprehensive understanding of the cardiovascular safety profiles of pharmacological agents, suggesting the necessity of blood pressure monitoring following administration.
  • ||||||||||  cisplatin / Generic mfg., Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Journal, BRCA Biomarker, PARP Biomarker:  Olaparib increases chemosensitivity by upregulating miR-125a-3p in ovarian cancer cells. (Pubmed Central) -  Mar 11, 2025   
    Regular monitoring and proactive management strategies are essential to mitigate risks and ensure patient safety. On the whole, the present study demonstrates that the increased expression of miR-125a-3p induces DNA damage and senescence in ovarian cancer cells, which enhances the therapeutic sensitivity.
  • ||||||||||  NUV-868 / Nuvation Bio
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Monotherapy:  NUV-868-01: NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Mar 11, 2025   
    P1/2,  N=82, Terminated, 
    On the whole, the present study demonstrates that the increased expression of miR-125a-3p induces DNA damage and senescence in ovarian cancer cells, which enhances the therapeutic sensitivity. N=657 --> 82 | Trial completion date: Nov 2026 --> Jul 2024 | Recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Jul 2024; The Sponsor has achieved its objectives.
  • ||||||||||  busulfan / Generic mfg.
    Trial completion date:  Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R (clinicaltrials.gov) -  Mar 11, 2025   
    P2,  N=60, Active, not recruiting, 
    N=657 --> 82 | Trial completion date: Nov 2026 --> Jul 2024 | Recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Jul 2024; The Sponsor has achieved its objectives. Trial completion date: Dec 2024 --> Aug 2025
  • ||||||||||  Retevmo (selpercatinib) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal, IO biomarker:  Transforming thyroid cancer management: the impact of neoadjuvant therapy. (Pubmed Central) -  Mar 10, 2025   
    Similarly, for medullary thyroid cancer, selpercatinib have exhibited interesting response rates, enhancing the feasibility of surgery with reduced morbidity in limited clinical case series of patients with RET mutations...The risk of adverse events, particularly related to the inhibition of the VEGF pathway, necessitates careful patient selection and management. The variability in tumor responses and the potential for serious complications underscore the need for continued research to refine these approaches in this difficult patient population.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Vericiguat (Agora 1) -  Mar 10, 2025 - Abstract #HEARTFAILURE2025HEART_FAILURE_2174;    
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Biomarker, Journal, Tumor mutational burden, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker:  Response to pembrolizumab in advanced prostate cancer with predictive biomarkers. (Pubmed Central) -  Mar 10, 2025   
    Neither MSI-H nor TMB-H, however, was sufficient for response. These results support biomarker testing for all patients with mPC and use of immunotherapy in select populations.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Enrollment closed:  Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC) (clinicaltrials.gov) -  Mar 10, 2025   
    P2,  N=28, Active, not recruiting, 
    Trial completion date: May 2028 --> Apr 2029 Recruiting --> Active, not recruiting
  • ||||||||||  tilarginine (L-NMMA) / Galera Therap
    Trial completion date, Mismatch repair, Tumor mutational burden, IO biomarker:  Phase Ib of L-NMMA and Pembrolizumab (clinicaltrials.gov) -  Mar 10, 2025   
    P1,  N=12, Active, not recruiting, 
    Recruiting --> Active, not recruiting Trial completion date: Dec 2024 --> Dec 2025
  • ||||||||||  Invanz (ertapenem) / Merck (MSD)
    Journal:  From Diarrhea to Bacteremia: Extended-Spectrum Beta-Lactamase (ESBL)-Producing Shigella in a Rare Clinical Scenario. (Pubmed Central) -  Mar 10, 2025   
    The patient tested negative for human immunodeficiency virus (HIV), had normal immunoglobulin levels, and was successfully treated with a 10-day course of ertapenem, achieving full recovery...It highlights the need for prompt diagnosis, antibiotic susceptibility testing, and targeted antimicrobial therapy, especially given the rising prevalence of antibiotic-resistant strains. A thorough investigation of predisposing factors and patient education on hygiene practices remains essential to prevent transmission and mitigate community outbreaks.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal:  A Case of Myasthenia Gravis: A Paraneoplastic Syndrome or an Immune-Related Disorder? (Pubmed Central) -  Mar 10, 2025   
    He had recently received two doses of 200 mg pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor...In summary, we present a case of MG with the presence of titin and striated muscle antibodies in a patient with metastatic RCC undergoing checkpoint immunomodulating therapy. Management remains challenging in patients with underlying malignancy treated with ICIs.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal:  Advanced Melanoma Management: A Case Report of Pembrolizumab Use in a Haemodialysis Patient. (Pubmed Central) -  Mar 10, 2025   
    Although she underwent surgical treatment for two oligoprogressions, the patient maintained treatment with pembrolizumab, now demonstrating a response duration of 20 months. The age and comorbidities in this case, coupled with the lack of robust scientific evidence on the use of immunotherapy in dialysis patients, illustrate the daily complexity of therapeutic decisions in oncology.
  • ||||||||||  Cervarix (recombinant human papillomavirus bivalent vaccine) / GSK, Japan Vaccine, Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant) / Merck (MSD)
    Review, Journal:  Human Papillomavirus Vaccination in Saudi Arabia: A Narrative Review of Current Evidence. (Pubmed Central) -  Mar 10, 2025   
    International collaboration, such as initiatives by the Gavi alliance and sustained research efforts, is critical to optimizing HPV vaccine efficacy, accessibility, and uptake. Through coordinated efforts, the global burden of HPV-related diseases can be significantly reduced, ultimately leading to improved public health outcomes.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Immunotherapy in cervical cancer: an innovative approach for better treatment outcomes. (Pubmed Central) -  Mar 10, 2025   
    Pembrolizumab, a PD-1 inhibitor, has been approved for PD-L1-positive cervical cancer, demonstrating durable responses...Key gaps include a lack of biomarkers for patient selection, insufficient understanding of TME dynamics, and suboptimal strategies for overcoming antigen heterogeneity and immune resistance. This review addresses these issues by providing a comprehensive analysis of the current landscape of cervical cancer immunotherapy, identifying critical barriers, and highlighting emerging approaches, such as combination therapies, novel immune targets, and strategies to modulate the TME, to guide future research and clinical practice.